Eli Lilly acquired global rights to MeiraGTx’s AAV‑AIPL1 retinal gene therapy with an upfront payment reported at $75 million, adding a late‑stage program destined for regulatory filings in the U.S. and Europe. The deal extends Lilly’s recent expansion into genetic medicines after prior gene therapy transactions and follows its strategy to build a diversified genetic‑medicines portfolio for rare ophthalmic disorders. Company statements highlight accelerated regulatory planning and integration into Lilly’s broader rare‑disease capabilities.